Monthly News Roundup - February 2015
Sanofi Receives FDA Approval for Basal Insulin Toujeo
The U.S. Food and Drug Administration has approved Sanofi’s Toujeo (insulin glargine [rDNA origin], a once-daily long-acting basal insulin for adults with type 1 or type 2 diabetes. In the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 27, 2015 Category: Pharmaceuticals Source Type: news
FDA Oks Lantus Follow-Up
(MedPage Today) -- Sanofi gets green light as patent on its top-selling insulin is set to expire. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 26, 2015 Category: Cardiology Source Type: news
FDA Approves Key Sanofi Diabetes Drug
The U.S. FDA has approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the drugmaker's top-selling insulin product Lantus. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 26, 2015 Category: Pharmaceuticals Source Type: news
Sanofi's Diabetes Drug Toujeo Gets U.S. ApprovalSanofi's Diabetes Drug Toujeo Gets U.S. Approval
The U.S. Food and Drug Administration (FDA) has approved Sanofi's new once-daily long-acting basal insulin Toujeo (insulin glargine 300 U/mL). Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
FDA approves Sanofi's diabetes drug Toujeo
(Reuters) - U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus. (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Sanofi's diabetes treatment Toujeo obtains FDA approval
Sanofi has received approval from the US Food and Drug Administration (FDA) for its Toujeo (insulin glargine [rDNA origin] injection, 300U/mL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 26, 2015 Category: Pharmaceuticals Source Type: news
Influence of Insulin & Glargine on Circulating EPCs in T2DMInfluence of Insulin & Glargine on Circulating EPCs in T2DM
Does insulin therapy protect against diabetic microvascular disease by increasing endothelial progenitor cells? Cardiovascular Diabetology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
insulin glargine (Lantus)
Title: insulin glargine (Lantus)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 12/23/2014 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 23, 2014 Category: Endocrinology Source Type: news
ORIGINALE: Fewer Cases of New Diabetes With InsulinORIGINALE: Fewer Cases of New Diabetes With Insulin
The 2.5-year follow-on study from the ORIGIN trial confirms the neutral effect of insulin glargine on CV events and cancer, while indicating that insulin may be able to reduce development of new diabetes. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 24, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Still No Heart Risks With Lantus in ORIGINALE
VIENNA (MedPage Today) -- Insulin glargine (Lantus) continued to carry no increased risk of cardiovascular events compared with standard care in an extension of the ORIGIN trial, researchers reported here. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 19, 2014 Category: American Health Source Type: news
Mylan to start Phase III trial of generic Advair Diskus, insulin analogue to Lantus
Global generic and specialty pharmaceuticals company Mylan is set to start a Phase III clinical trial of its generic version of GlaxoSmithKline's (GSK) Advair Diskus and its insulin analogue to Sanofi's Lantus. (Source: Drug Development Technology)
Source: Drug Development Technology - September 16, 2014 Category: Pharmaceuticals Source Type: news
Biosimilar Lantus Approved in Europe
(MedPage Today) -- A biosimilar version of the top-selling diabetes drug Lantus has won marketing authorization in the European Union, drugmakers Eli Lilly and Boehringer Ingelheim announced today. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 10, 2014 Category: Cardiology Source Type: news
First Biosimilar Insulin, Glargine, Approved in EUFirst Biosimilar Insulin, Glargine, Approved in EU
The European Commission has approved an insulin glargine product from Lilly and Boehringer Ingelheim, a so-called biosimilar of Sanofi's insulin glargine, a basal insulin. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 10, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Another Insulin Closer to FDA Assessment
(MedPage Today) -- Once-daily insulin peglispro proved non-inferior to insulin glargine (Lantus) in two of the late-stage trials in the IMAGINE program, drugmaker Eli Lilly announced. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 9, 2014 Category: Primary Care Source Type: news
Lilly's diabetes drug trumps Sanofi's in late-stage trials
(Reuters) - Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA's approved drug, Lantus, in reducing blood sugar levels in late-stage trials. (Source: Reuters: Health)
Source: Reuters: Health - September 4, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
